Novartis has signed a licensing deal with PTC Therapeutics for an experimental Huntington’s disease treatment, with an upfront payment of $1 billion. The agreement also includes the potential for another $1.9 billion in payments based on hitting development, regulatory, and commercial milestones. Novartis CEO Vas Narasimhan stated that this deal aims to strengthen their neuroscience pipeline and shows their commitment to exploring new approaches for neurodegenerative diseases with high unmet needs. The deal highlights Novartis’ strategic focus on innovative treatments for serious health conditions.
Source link
Novartis back in Huntington’s with $1B licensing deal with PTC
